陣痛促進剤(子宮収縮剤)の世界市場2016-2026

【英語タイトル】Oxytocic Pharmaceuticals Market: Labour Induction Segment Expected to Register Moderate Y-o-Y Growth Throughout the Forecast Period: Global Industry Analysis & Opportunity Assessment, 2016 - 2026

Future Market Insightsが出版した調査資料(FMI703081)・商品コード:FMI703081
・発行会社(調査会社):Future Market Insights
・発行日:2017年1月17日
・ページ数:217
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Individual (single user)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
EnterpriseUSD10,000 ⇒換算¥1,130,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、陣痛促進剤(子宮収縮剤)の世界市場について調査・分析し、陣痛促進剤(子宮収縮剤)の世界市場動向、陣痛促進剤(子宮収縮剤)の世界市場規模、市場予測、セグメント別陣痛促進剤(子宮収縮剤)市場分析、地域別市場規模(北米市場、南米市場、アジア市場、日本市場、ヨーロッパ市場など)、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

With a CAGR of 10.1%, the post-partum haemorrhage segment anticipated to lead the global oxytocic pharmaceuticals market in the coming decade
The post-partum haemorrhage segment was estimated to account for more than 75% market share of the global oxytocic pharmaceuticals market by the end of 2016 and is expected to gain more than 200 BPS in its market share by 2026. The post-partum haemorrhage segment is expected to register high Y-o-Y growth during the forecast period and is projected to remain the dominant segment during the forecast period. The post-partum haemorrhage segment is estimated to create absolute $ opportunity of more than US$ 5 Mn in 2017 over 2016. This segment dominated the global oxytocic pharmaceuticals market in terms of revenue in 2015, and the trend is projected to continue throughout the period of forecast.

Labour induction during childbirth is likely to boost the post-partum haemorrhage segment

Increasing childbirth using labour induction proves to be driving factor for the post-partum haemorrhage condition. There are certain situations – for instance, pre-eclampsia – where continuing the pregnancy is dangerous to the mother, or there are instances where women are uncomfortable, sore and tired. In such cases, labour is induced for convenience rather than medical reasons. However, labour induction increases the chances of post-partum haemorrhage. According to the World Health Organization, the rate of labour induction in developing countries is lower; but in developed countries, the rates are relatively high, which is creating a positive impact on the post-partum haemorrhage segment. Another factor which is likely to fuel the revenue growth of the post-partum haemorrhage segment is the increasing age of mothers. Older and heavier women and women who are smokers are more likely to bleed heavily after delivery. The ratio of getting pregnant after a certain age in life has increased in almost all the regions across the globe and this is creating robust development in the global oxytocic pharmaceuticals market, and specifically in the post-partum haemorrhage segment. Africa’s contribution to the prevalence of post-partum haemorrhage is likely to increase due to lack of healthcare infrastructure and awareness regarding pregnancy

The post-partum haemorrhage segment is the most attractive segment by indication in the North America oxytocic pharmaceuticals market, with a market attractiveness index of 3.9 estimated during the forecast period. In the Latin America region, the post-partum haemorrhage segment is estimated to reach a market attractiveness index of 3.7 due to increasing adolescent pregnancies. A majority of these pregnancies occur in Brazil in Latin America. An increase in labour induction procedures in the region is responsible for positioning post-partum haemorrhage as the most attractive indication segment. The MEA region represents a higher prevalence of post-partum haemorrhage among all the regions owing to lack of proper nutrition to pregnant women. Africa’s contribution to the prevalence of post-partum haemorrhage in the MEA region is on the higher end, owing to a lack of healthcare infrastructure and awareness regarding pregnancy related aspects among African women. Prevalence of post-partum haemorrhage is as high as 25.7% in African countries and 8.5% in Asian countries. In China, the post-partum haemorrhage segment is anticipated to record a market attractiveness index of 3.8 during the forecast period. A large pool of population and China’s altered single child policy to two children policy may likely increase the incidence of post-partum haemorrhage.

Opportunities in the global oxytocic pharmaceuticals market owing to rising instances of post-partum haemorrhage

Companies functioning in the global oxytocic pharmaceuticals market can reap larger market revenue from untapped markets in Asia and Africa where the prevalence of post-partum haemorrhage is on the higher side in comparison with other regions. Imparting awareness pertaining to pregnancy among the women in these regions can help create more market opportunities for existing as well as new entrants in the global oxytocic pharmaceuticals market.

【レポートの目次】

Table Of Content

1. Executive Summary

2. Market Introduction

2.1. Market Definition

2.2. Market Taxonomy

3. Global Oxytocic Pharmaceuticals Market Analysis Scenario

3.1. Market Size (US$ Mn) and Forecast

3.1.1. Market Size and Y-o-Y Growth

3.1.2. Absolute $ Opportunity

4. Market Dynamics

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

4.5. Number of procedures by Indications per region (2015-2026)

4.6. Number of procedures by End User per region (2015-2026)

4.7. Number of cervical ripening procedures by region (2015)

4.8. Comparative drugs list other than Oxytocin

5. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By Indication

5.1. Introduction

5.2. Basis Point Share (BPS) Analysis By Indication Type

5.3. Y-o-Y Growth Projections By Indication Type

5.4. Market Value Forecast By Indication, 2016–2026

5.4.1. Abortion Induced Incomplete

5.4.2. Inevitable Abortion

5.4.3. Postpartum Hemorrhage

5.4.4. Labor Induction

5.4.5. Labor Arrest

5.5. Market Attractiveness By Indication

6. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By End User

6.1. Introduction

6.2. Basis Point Share (BPS) Analysis By End User

6.3. Y-o-Y Growth Projections By End User

6.4. Market Value Forecast By End User, 2016–2026

6.4.1. Hospitals

6.4.2. Maternity Clinics

6.5. Market Attractiveness By End User

7. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By Route of Administration

7.1. Introduction

7.2. Basis Point Share (BPS) Analysis By Route of Administration

7.3. Y-o-Y Growth Projections By Route of Administration

7.4. Market Value Forecast By Route of Administration, 2016–2026

7.4.1. Intravenous Infusion/Injection

7.4.2. Intramuscular Injection

7.5. Market Attractiveness By Route of Administration

8. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By Source of Origin

8.1. Introduction

8.2. Basis Point Share (BPS) Analysis By Source of Origin

8.3. Y-o-Y Growth Projections By Source of Origin

8.4. Market Value Forecast By Source of Origin, 2016–2026

8.4.1. Synthetic Oxytocin Derivative

8.4.2. Natural Oxytocin (Animal Pituitary Extract)

8.5. Market Attractiveness By Source of Origin

9. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By Region

9.1. Basis Point Share (BPS) Analysis By Region

9.2. Y-o-Y Growth Projections By Region

9.3. Market Value Forecast By Region

9.3.1. North America

9.3.2. Latin America

9.3.3. Western Europe

9.3.4. Eastern Europe

9.3.5. China

9.3.6. Japan

9.3.7. APEJC

9.3.8. MEA

9.4. Market Attractiveness By Region

10. North America Oxytocic Pharmaceuticals Market Analysis and Forecast

10.1.Introduction

10.1.1. Basis Point Share (BPS) Analysis By Country

10.1.2. Y-o-Y Growth Projections By Country

10.2.Market Value Forecast By Indication, 2016–2026

10.2.1. Abortion Induced Incomplete

10.2.2. Inevitable Abortion

10.2.3. Postpartum Hemorrhage

10.2.4. Labor Induction

10.2.5. Labor Arrest

10.3.Market Value Forecast By End User, 2016–2026

10.3.1. Hospitals

10.3.2. Maternity Clinics

10.4.Market Value Forecast By Route of Administration, 2016–2026

10.4.1. Intravenous Infusion/Injection

10.4.2. Intramuscular Injection

10.5.Market Value Forecast By Source of Origin, 2016–2026

10.5.1. Synthetic Oxytocin Derivative

10.5.2. Natural Oxytocin (Animal Pituitary Extract)

10.6.Market Value Forecast By Country, 2016–2026

10.6.1. US

10.6.2. Canada

10.7.Market Attractiveness Analysis

10.7.1. By Indication

10.7.2. By End User

10.7.3. By Route of Administration

10.7.4. By Source of Origin

10.7.5. By Country

10.8. Prominent Trends

11. Latin America Oxytocic Pharmaceuticals Market Analysis and Forecast

11.1.Introduction

11.1.1. Basis Point Share (BPS) Analysis By Country

11.1.2. Y-o-Y Growth Projections By Country

11.2.Market Value Forecast By Indication, 2016–2026

11.2.1. Abortion Induced Incomplete

11.2.2. Inevitable Abortion

11.2.3. Postpartum Hemorrhage

11.2.4. Labor Induction

11.2.5. Labor Arrest

11.3.Market Value Forecast By End User, 2016–2026

11.3.1. Hospitals

11.3.2. Maternity Clinics

11.4.Market Value Forecast By Route of Administration, 2016–2026

11.4.1. Intravenous Infusion/Injection

11.4.2. Intramuscular Injection

11.5.Market Value Forecast By Source of Origin, 2016–2026

11.5.1. Synthetic Oxytocin Derivative

11.5.2. Natural Oxytocin (Animal Pituitary Extract)

11.6.Market Value Forecast By Country, 2016–2026

11.6.1. Brazil

11.6.2. Mexico

11.6.3. Rest of Latin America

11.7.Market Attractiveness Analysis

11.7.1. By Indication

11.7.2. By End User

11.7.3. By Route of Administration

11.7.4. By Source of Origin

11.7.5. By Country

11.8. Prominent Trends

12. Western Europe Oxytocic Pharmaceuticals Market Analysis and Forecast

12.1.Introduction

12.1.1. Basis Point Share (BPS) Analysis By Country

12.1.2. Y-o-Y Growth Projections By Country

12.2.Market Value Forecast By Indication, 2016–2026

12.2.1. Abortion Induced Incomplete

12.2.2. Inevitable Abortion

12.2.3. Postpartum Hemorrhage

12.2.4. Labor Induction

12.2.5. Labor Arrest

12.3.Market Value Forecast By End User, 2016–2026

12.3.1. Hospitals

12.3.2. Maternity Clinics

12.4.Market Value Forecast By Route of Administration, 2016–2026

12.4.1. Intravenous Infusion/Injection

12.4.2. Intramuscular Injection

12.5.Market Value Forecast By Source of Origin, 2016–2026

12.5.1. Synthetic Oxytocin Derivative

12.5.2. Natural Oxytocin (Animal Pituitary Extract)

12.6.Market Value Forecast By Country, 2016–2026

12.6.1. UK

12.6.2. France

12.6.3. Germany

12.6.4. Italy

12.6.5. Spain

12.6.6. Benelux

12.6.7. Rest of Western Europe

12.7.Market Attractiveness Analysis

12.7.1. By Indication

12.7.2. By End User

12.7.3. By Route of Administration

12.7.4. By Source of Origin

12.7.5. By Country

12.8. Prominent Trends

13. Eastern Europe Oxytocic Pharmaceuticals Market Analysis and Forecast

13.1.Introduction

13.1.1. Basis Point Share (BPS) Analysis By Country

13.1.2. Y-o-Y Growth Projections By Country

13.2.Market Value Forecast By Indication, 2016–2026

13.2.1. Abortion Induced Incomplete

13.2.2. Inevitable Abortion

13.2.3. Postpartum Hemorrhage

13.2.4. Labor Induction

13.2.5. Labor Arrest

13.3.Market Value Forecast By End User, 2016–2026

13.3.1. Hospitals

13.3.2. Maternity Clinics

13.4.Market Value Forecast By Route of Administration, 2016–2026

13.4.1. Intravenous Infusion/Injection

13.4.2. Intramuscular Injection

13.5.Market Value Forecast By Source of Origin, 2016–2026

13.5.1. Synthetic Oxytocin Derivative

13.5.2. Natural Oxytocin (Animal Pituitary Extract)

13.6.Market Value Forecast By Country, 2016–2026

13.6.1. Russia

13.6.2. Poland

13.6.3. Rest of Eastern Europe

13.7.Market Attractiveness Analysis

13.7.1. By Indication

13.7.2. By End User

13.7.3. By Route of Administration

13.7.4. By Source of Origin

13.7.5. By Country

13.8. Prominent Trends

14. APEJC Oxytocic Pharmaceuticals Market Analysis and Forecast

14.1.Introduction

14.1.1. Basis Point Share (BPS) Analysis By Country

14.1.2. Y-o-Y Growth Projections By Country

14.2.Market Value Forecast By Indication, 2016–2026

14.2.1. Abortion Induced Incomplete

14.2.2. Inevitable Abortion

14.2.3. Postpartum Hemorrhage

14.2.4. Labor Induction

14.2.5. Labor Arrest

14.3.Market Value Forecast By End User, 2016–2026

14.3.1. Hospitals

14.3.2. Maternity Clinics

14.4.Market Value Forecast By Route of Administration, 2016–2026

14.4.1. Intravenous Infusion/Injection

14.4.2. Intramuscular Injection

14.5.Market Value Forecast By Source of Origin, 2016–2026

14.5.1. Synthetic Oxytocin Derivative

14.5.2. Natural Oxytocin (Animal Pituitary Extract)

14.6.Market Value Forecast By Country, 2016–2026

14.6.1. India

14.6.2. Australia & New Zealand

14.6.3. ASEAN

14.6.4. Rest of APEJC

14.7.Market Attractiveness Analysis

14.7.1. By Indication

14.7.2. By End User

14.7.3. By Route of Administration

14.7.4. By Source of Origin

14.7.5. By Country

14.8. Prominent Trends

15. Japan Oxytocic Pharmaceuticals Market Analysis and Forecast

15.1.Introduction

15.1.1. Basis Point Share (BPS) Analysis By Country

15.1.2. Y-o-Y Growth Projections By Country

15.2.Market Value Forecast By Indication, 2016–2026

15.2.1. Abortion Induced Incomplete

15.2.2. Inevitable Abortion

15.2.3. Postpartum Hemorrhage

15.2.4. Labor Induction

15.2.5. Labor Arrest

15.3.Market Value Forecast By End User, 2016–2026

15.3.1. Hospitals

15.3.2. Maternity Clinics

15.4.Market Value Forecast By Route of Administration, 2016–2026

15.4.1. Intravenous Infusion/Injection

15.4.2. Intramuscular Injection

15.5.Market Value Forecast By Source of Origin, 2016–2026

15.5.1. Synthetic Oxytocin Derivative

15.5.2. Natural Oxytocin (Animal Pituitary Extract)

15.6.Market Attractiveness Analysis

15.6.1. By Indication

15.6.2. By End User

15.6.3. By Route of Administration

15.6.4. By Source of Origin

15.7. Prominent Trends

16. MEA Oxytocic Pharmaceuticals Market Analysis and Forecast

16.1.Introduction

16.1.1. Basis Point Share (BPS) Analysis By Country

16.1.2. Y-o-Y Growth Projections By Country

16.2.Market Value Forecast By Indication, 2016–2026

16.2.1. Abortion Induced Incomplete

16.2.2. Inevitable Abortion

16.2.3. Postpartum Hemorrhage

16.2.4. Labor Induction

16.2.5. Labor Arrest

16.3.Market Value Forecast By End User, 2016–2026

16.3.1. Hospitals

16.3.2. Maternity Clinics

16.4.Market Value Forecast By Route of Administration, 2016–2026

16.4.1. Intravenous Infusion/Injection

16.4.2. Intramuscular Injection

16.5.Market Value Forecast By Source of Origin, 2016–2026

16.5.1. Synthetic Oxytocin Derivative

16.5.2. Natural Oxytocin (Animal Pituitary Extract)

16.6.Market Value Forecast By Country, 2016–2026

16.6.1. GCC Countries

16.6.2. South Africa

16.6.3. Rest of MEA

16.7.Market Attractiveness Analysis

16.7.1. By Indication

16.7.2. By End User

16.7.3. By Route of Administration

16.7.4. By Source of Origin

16.7.5. By Country

16.8. Prominent Trends

17. China Oxytocic Pharmaceuticals Market Analysis and Forecast

17.1.Introduction

17.1.1. Basis Point Share (BPS) Analysis By Country

17.1.2. Y-o-Y Growth Projections By Country

17.2.Market Value Forecast By Indication, 2016–2026

17.2.1. Abortion Induced Incomplete

17.2.2. Inevitable Abortion

17.2.3. Postpartum Hemorrhage

17.2.4. Labor Induction

17.2.5. Labor Arrest

17.3.Market Value Forecast By End User, 2016–2026

17.3.1. Hospitals

17.3.2. Maternity Clinics

17.4.Market Value Forecast By Route of Administration, 2016–2026

17.4.1. Intravenous Infusion/Injection

17.4.2. Intramuscular Injection

17.5.Market Value Forecast By Source of Origin, 2016–2026

17.5.1. Synthetic Oxytocin Derivative

17.5.2. Natural Oxytocin (Animal Pituitary Extract)

17.6.Market Attractiveness Analysis

17.6.1. By Indication

17.6.2. By End User

17.6.3. By Route of Administration

17.6.4. By Source of Origin



【レポートのキーワード】

陣痛促進剤、子宮収縮剤、分娩促進薬

★調査レポート[陣痛促進剤(子宮収縮剤)の世界市場2016-2026] (コード:FMI703081)販売に関する免責事項を必ずご確認ください。
★調査レポート[陣痛促進剤(子宮収縮剤)の世界市場2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆